ImmBio TherapeuticsImmBio Therapeutics Ltd is a sister company to ImmBio, established to use HspC technology to identify therapeutic products in otherwise difficult-to-address areas. ImmBio Therapeutics has been awarded a Proof of Principle grant from the East of England Development Agency (“EEDA”). Key advantages of the platform being developed are
Another consequence of the approach mirroring the normal course of pathogen defence is that the safety profile is expected to be excellent.
|


